Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis

Tania Jain, Katie L. Kunze, M’hamed Temkit, Daniel K. Partain, Mrinal S. Patnaik, James L. Slack, Nandita Khera, William J. Hogan, Vivek Roy, Pierre Noel, Jose F. Leis, Lisa Z. Sproat, Veena Fauble, Ruben A. Mesa, Jeanne Palmer

Research output: Contribution to journalArticle

Abstract

The aim of this study is to compare clinical outcomes of patients who underwent allogeneic stem cell transplantation (HCT) for myelofibrosis with reduced intensity conditioning (RIC) using either Busulfan Fludarabine (BuFlu), Fludarabine Bis-chlorethyl-nitroso-urea/ carmustine Melphalan (FBM) or Fludarabine Melphalan (FluMel) regimens. Sixty-one patients were identified who underwent HCT with one of these RIC regimens. Overall survival (OS) was not different in the 3 groups. However, 100% donor chimerism was seen in more frequently at day +30 and day +100 in patients who received FBM or FluMel than BuFlu, in both CD3 and CD33 fractions. For instance, 100% donor chimerism in CD33 fraction was present in 100% patients in FBM cohort, 90% in FluMel cohort while 44% in BuFlu cohort at day +100. Acute graft-versus host disease, grade 2–4 and grade 3–4, was not statistically different in the 3 groups (BuFlu 47 and 35%, FBM 68 and 27%, FluMel 68 and 46%; p = 0.31 and 0.45). Relapses and non-relapse mortality was also not statistically significantly different. Our study shows similar OS with these 3 RIC regimens in myelofibrosis; although donor chimerism at day +30 and day +100 was better in patients who received FBM and FluMel.

Original languageEnglish (US)
Pages (from-to)204-211
Number of pages8
JournalBone marrow transplantation
Volume54
Issue number2
DOIs
StatePublished - Feb 1 2019
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Hematopoietic Stem Cell Transplantation
Melphalan
Busulfan
Chimerism
Tissue Donors
fludarabine
Carmustine
Survival
Stem Cell Transplantation
Graft vs Host Disease
Urea
Recurrence

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. / Jain, Tania; Kunze, Katie L.; Temkit, M’hamed; Partain, Daniel K.; Patnaik, Mrinal S.; Slack, James L.; Khera, Nandita; Hogan, William J.; Roy, Vivek; Noel, Pierre; Leis, Jose F.; Sproat, Lisa Z.; Fauble, Veena; Mesa, Ruben A.; Palmer, Jeanne.

In: Bone marrow transplantation, Vol. 54, No. 2, 01.02.2019, p. 204-211.

Research output: Contribution to journalArticle

Jain, T, Kunze, KL, Temkit, M, Partain, DK, Patnaik, MS, Slack, JL, Khera, N, Hogan, WJ, Roy, V, Noel, P, Leis, JF, Sproat, LZ, Fauble, V, Mesa, RA & Palmer, J 2019, 'Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis', Bone marrow transplantation, vol. 54, no. 2, pp. 204-211. https://doi.org/10.1038/s41409-018-0226-1
Jain, Tania ; Kunze, Katie L. ; Temkit, M’hamed ; Partain, Daniel K. ; Patnaik, Mrinal S. ; Slack, James L. ; Khera, Nandita ; Hogan, William J. ; Roy, Vivek ; Noel, Pierre ; Leis, Jose F. ; Sproat, Lisa Z. ; Fauble, Veena ; Mesa, Ruben A. ; Palmer, Jeanne. / Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. In: Bone marrow transplantation. 2019 ; Vol. 54, No. 2. pp. 204-211.
@article{f76f261ae6b445f0a1208090f14d6aa4,
title = "Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis",
abstract = "The aim of this study is to compare clinical outcomes of patients who underwent allogeneic stem cell transplantation (HCT) for myelofibrosis with reduced intensity conditioning (RIC) using either Busulfan Fludarabine (BuFlu), Fludarabine Bis-chlorethyl-nitroso-urea/ carmustine Melphalan (FBM) or Fludarabine Melphalan (FluMel) regimens. Sixty-one patients were identified who underwent HCT with one of these RIC regimens. Overall survival (OS) was not different in the 3 groups. However, 100{\%} donor chimerism was seen in more frequently at day +30 and day +100 in patients who received FBM or FluMel than BuFlu, in both CD3 and CD33 fractions. For instance, 100{\%} donor chimerism in CD33 fraction was present in 100{\%} patients in FBM cohort, 90{\%} in FluMel cohort while 44{\%} in BuFlu cohort at day +100. Acute graft-versus host disease, grade 2–4 and grade 3–4, was not statistically different in the 3 groups (BuFlu 47 and 35{\%}, FBM 68 and 27{\%}, FluMel 68 and 46{\%}; p = 0.31 and 0.45). Relapses and non-relapse mortality was also not statistically significantly different. Our study shows similar OS with these 3 RIC regimens in myelofibrosis; although donor chimerism at day +30 and day +100 was better in patients who received FBM and FluMel.",
author = "Tania Jain and Kunze, {Katie L.} and M’hamed Temkit and Partain, {Daniel K.} and Patnaik, {Mrinal S.} and Slack, {James L.} and Nandita Khera and Hogan, {William J.} and Vivek Roy and Pierre Noel and Leis, {Jose F.} and Sproat, {Lisa Z.} and Veena Fauble and Mesa, {Ruben A.} and Jeanne Palmer",
year = "2019",
month = "2",
day = "1",
doi = "10.1038/s41409-018-0226-1",
language = "English (US)",
volume = "54",
pages = "204--211",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis

AU - Jain, Tania

AU - Kunze, Katie L.

AU - Temkit, M’hamed

AU - Partain, Daniel K.

AU - Patnaik, Mrinal S.

AU - Slack, James L.

AU - Khera, Nandita

AU - Hogan, William J.

AU - Roy, Vivek

AU - Noel, Pierre

AU - Leis, Jose F.

AU - Sproat, Lisa Z.

AU - Fauble, Veena

AU - Mesa, Ruben A.

AU - Palmer, Jeanne

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The aim of this study is to compare clinical outcomes of patients who underwent allogeneic stem cell transplantation (HCT) for myelofibrosis with reduced intensity conditioning (RIC) using either Busulfan Fludarabine (BuFlu), Fludarabine Bis-chlorethyl-nitroso-urea/ carmustine Melphalan (FBM) or Fludarabine Melphalan (FluMel) regimens. Sixty-one patients were identified who underwent HCT with one of these RIC regimens. Overall survival (OS) was not different in the 3 groups. However, 100% donor chimerism was seen in more frequently at day +30 and day +100 in patients who received FBM or FluMel than BuFlu, in both CD3 and CD33 fractions. For instance, 100% donor chimerism in CD33 fraction was present in 100% patients in FBM cohort, 90% in FluMel cohort while 44% in BuFlu cohort at day +100. Acute graft-versus host disease, grade 2–4 and grade 3–4, was not statistically different in the 3 groups (BuFlu 47 and 35%, FBM 68 and 27%, FluMel 68 and 46%; p = 0.31 and 0.45). Relapses and non-relapse mortality was also not statistically significantly different. Our study shows similar OS with these 3 RIC regimens in myelofibrosis; although donor chimerism at day +30 and day +100 was better in patients who received FBM and FluMel.

AB - The aim of this study is to compare clinical outcomes of patients who underwent allogeneic stem cell transplantation (HCT) for myelofibrosis with reduced intensity conditioning (RIC) using either Busulfan Fludarabine (BuFlu), Fludarabine Bis-chlorethyl-nitroso-urea/ carmustine Melphalan (FBM) or Fludarabine Melphalan (FluMel) regimens. Sixty-one patients were identified who underwent HCT with one of these RIC regimens. Overall survival (OS) was not different in the 3 groups. However, 100% donor chimerism was seen in more frequently at day +30 and day +100 in patients who received FBM or FluMel than BuFlu, in both CD3 and CD33 fractions. For instance, 100% donor chimerism in CD33 fraction was present in 100% patients in FBM cohort, 90% in FluMel cohort while 44% in BuFlu cohort at day +100. Acute graft-versus host disease, grade 2–4 and grade 3–4, was not statistically different in the 3 groups (BuFlu 47 and 35%, FBM 68 and 27%, FluMel 68 and 46%; p = 0.31 and 0.45). Relapses and non-relapse mortality was also not statistically significantly different. Our study shows similar OS with these 3 RIC regimens in myelofibrosis; although donor chimerism at day +30 and day +100 was better in patients who received FBM and FluMel.

UR - http://www.scopus.com/inward/record.url?scp=85047312582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047312582&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0226-1

DO - 10.1038/s41409-018-0226-1

M3 - Article

VL - 54

SP - 204

EP - 211

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -